IN2014DN09068A - - Google Patents

Info

Publication number
IN2014DN09068A
IN2014DN09068A IN9068DEN2014A IN2014DN09068A IN 2014DN09068 A IN2014DN09068 A IN 2014DN09068A IN 9068DEN2014 A IN9068DEN2014 A IN 9068DEN2014A IN 2014DN09068 A IN2014DN09068 A IN 2014DN09068A
Authority
IN
India
Prior art keywords
methyl
dmydropyridin
morpholinomethyl
pyran
tetrahydro
Prior art date
Application number
Inventor
Kevin Wayne Kuntz
Kuan Chun Huang
Hyeong Wook Choi
Kristen Sanders
Steven Mathieu
Arani Chanda
Frank Fang
Original Assignee
Epizyme Inc
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc, Eisai R&D Man Co Ltd filed Critical Epizyme Inc
Publication of IN2014DN09068A publication Critical patent/IN2014DN09068A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Provided herein is N-((4,6-dimethyl-2-oxo-l,2-dmydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4- yl)amino)-4-methyl-4'-(morpholinomethyl)-[l , -biphenyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound.
IN9068DEN2014 2012-04-13 2013-04-11 IN2014DN09068A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261624215P 2012-04-13 2012-04-13
PCT/US2013/036193 WO2013155317A1 (en) 2012-04-13 2013-04-11 Salt form of a human hi stone methyltransf erase ezh2 inhibitor

Publications (1)

Publication Number Publication Date
IN2014DN09068A true IN2014DN09068A (en) 2015-05-22

Family

ID=49328166

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9068DEN2014 IN2014DN09068A (en) 2012-04-13 2013-04-11

Country Status (25)

Country Link
US (6) US9394283B2 (en)
EP (4) EP3628670B1 (en)
JP (3) JP6255382B2 (en)
KR (3) KR20220123339A (en)
CN (2) CN104603130B (en)
AU (2) AU2013245878B2 (en)
BR (1) BR112014025508B1 (en)
CA (1) CA2870005C (en)
CY (2) CY1119383T1 (en)
DK (3) DK3184523T3 (en)
ES (3) ES2617379T3 (en)
HR (2) HRP20170295T1 (en)
HU (3) HUE045353T2 (en)
IL (4) IL296199B1 (en)
IN (1) IN2014DN09068A (en)
LT (2) LT2836491T (en)
MX (1) MX362339B (en)
NZ (1) NZ700761A (en)
PL (3) PL3184523T3 (en)
PT (3) PT3628670T (en)
RS (2) RS55690B1 (en)
RU (1) RU2658911C2 (en)
SG (3) SG10201912109QA (en)
SI (2) SI2836491T1 (en)
WO (1) WO2013155317A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3438B1 (en) 2011-04-13 2019-10-20 Epizyme Inc Aryl- or heteroaryl-substituted benzene compounds
US9051269B2 (en) 2011-11-18 2015-06-09 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
NZ628762A (en) 2012-02-10 2016-07-29 Constellation Pharmaceuticals Inc Modulators of methyl modifying enzymes, compositions and uses thereof
KR20220123339A (en) 2012-04-13 2022-09-06 에피자임, 인코포레이티드 Salt form of a human histone methyltransferase ezh2 inhibitor
JP6340361B2 (en) 2012-04-13 2018-06-06 エピザイム，インコーポレイティド Combination therapy to treat cancer
WO2013173441A2 (en) 2012-05-16 2013-11-21 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
RU2658919C2 (en) 2012-10-15 2018-06-26 Эпизайм, Инк. Substituted benzene compounds
NZ746054A (en) * 2012-10-15 2020-07-31 Epizyme Inc Methods of treating cancer
EP2970305B1 (en) 2013-03-15 2017-02-22 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EA030196B1 (en) 2013-04-30 2018-07-31 Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед Enhancer of zeste homolog 2 inhibitors
RU2016104044A (en) 2013-07-10 2017-08-15 Глэксосмитклайн Интеллекчуал Проперти (Nо.2) Лимитед ZESTE Homolog Amplifier Inhibitors 2
US9969716B2 (en) 2013-08-15 2018-05-15 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
FI3057962T3 (en) 2013-10-16 2023-11-03 Epizyme Inc Hydrochloride salt form for ezh2 inhibition
EP3057594A4 (en) * 2013-10-18 2017-06-07 Epizyme, Inc. Method of treating cancer
US9738630B2 (en) 2013-11-19 2017-08-22 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
EA201691079A1 (en) 2013-12-06 2017-03-31 Эпизим, Инк. COMBINED THERAPY FOR THE TREATMENT OF ONCOLOGICAL DISEASE
MX2021007651A (en) 2014-06-17 2021-08-11 Epizyme Inc Ezh2 inhibitors for treating lymphoma.
DK3157928T3 (en) 2014-06-20 2019-05-20 Constellation Pharmaceuticals Inc CRYSTALLIC FORMS OF 2 - ((4S) -6- (4-CHLOROPHENYL) -1-METHYL-4H-BENZO [C] ISOXAZOLO [4,5-E] AZEPIN-4-YL) ACETAMIDE
MX2021007003A (en) 2014-10-16 2022-08-09 Epizyme Inc Method for treating cancer.
AU2015350108B2 (en) * 2014-11-17 2021-04-08 Eisai R&D Management Co., Ltd. Method for treating cancer
TW201636344A (en) 2014-12-05 2016-10-16 美國禮來大藥廠 Inhibitors of EZH2
SG11201708286PA (en) 2015-04-20 2017-11-29 Epizyme Inc Combination therapy for treating cancer
EA201890009A1 (en) 2015-06-10 2018-07-31 Эпизайм, Инк. EZH2 INHIBITORS FOR TREATING LYMPHOMA
CA2996412A1 (en) 2015-08-24 2017-03-02 Epizyme, Inc. Method for treating cancer
TW201718598A (en) 2015-08-27 2017-06-01 美國禮來大藥廠 Inhibitors of EZH2
US10577350B2 (en) 2015-08-28 2020-03-03 Constellation Pharmaceuticals, Inc. Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
WO2017132518A1 (en) 2016-01-29 2017-08-03 Epizyme, Inc. Combination therapy for treating cancer
CA3025933A1 (en) 2016-06-01 2017-12-07 Epizyme, Inc. Use of ezh2 inhibitors for treating cancer
EP3471830A4 (en) 2016-06-17 2020-02-26 Epizyme Inc Ezh2 inhibitors for treating cancer
US10457640B2 (en) 2016-10-19 2019-10-29 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of EZH2
US11214561B2 (en) * 2017-01-25 2022-01-04 Ancureall Pharmaceutical (Shanghai) Co., Ltd. Histone methyltransferase EZH2 inhibitor, preparation method and pharmaceutical use thereof
US11642346B2 (en) 2017-03-31 2023-05-09 Epizyme, Inc. Combination therapy for treating cancer
EP3630080A4 (en) 2017-06-02 2021-03-10 Epizyme, Inc. Use of ezh2 inhibitors for treating cancer
US11452727B2 (en) 2017-09-05 2022-09-27 Epizyme, Inc. Combination therapy for treating cancer
EP3823671B1 (en) 2018-07-09 2024-02-07 Fondation Asile Des Aveugles Inhibition of prc2 subunits to treat eye disorders
CN114555112A (en) 2019-08-22 2022-05-27 朱诺治疗学股份有限公司 Combination therapy of T cell therapy and ZESTE enhancer homolog 2(EZH2) inhibitors and related methods
AU2020408395A1 (en) * 2019-12-20 2022-07-07 Epizyme, Inc. Crystalline hydrobromide salt of a EZH2 inhibitor, its preparation and pharmaceutical composition useful for the treatment of cancer
WO2022208552A1 (en) * 2021-03-31 2022-10-06 Msn Laboratories Private Limited, R&D Center Crystalline forms of [1,1'-Biphenyl]-3-carboxamide, N-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-5-[ethyl(tetrahydro-2H-pyran-4-yl)amino]-4-methyl-4'-(4-morpholinylmethyl)-, hydrobromide (1:1) and process for its preparation thereof

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0733729A (en) 1993-07-26 1995-02-03 Kirin Brewery Co Ltd Production of n-cyano-n'-substituted-arylcarboxyimidamide compound
NZ277556A (en) 1993-12-27 1997-06-24 Eisai Co Ltd N-phenyl(alkyl)- and n-pyridyl(alkyl)anthranilic acid derivatives; intermediates
DE19516776A1 (en) 1995-05-10 1996-11-14 Boehringer Ingelheim Int Chromatin regulatory genes
US5741819A (en) 1995-06-07 1998-04-21 3-Dimensional Pharmaceuticals, Inc. Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors
JP3906935B2 (en) 1995-12-18 2007-04-18 杏林製薬株式会社 N-substituted dioxothiazolidylbenzamide derivative and process for producing the same
WO2000018725A1 (en) 1998-09-30 2000-04-06 The Procter & Gamble Company 2-substituted ketoamides
UA71587C2 (en) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Anthranilic acid amides and use thereof as medicaments
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
DK1357111T3 (en) 2000-12-28 2009-11-02 Shionogi & Co 2-pyridone derivatives with affinity for cannabinoid type 2 receptor
US7700293B2 (en) 2001-08-02 2010-04-20 The Regents Of The University Of Michigan Expression profile of prostate cancer
TW200303304A (en) * 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds
WO2003070277A1 (en) 2002-02-19 2003-08-28 Shionogi & Co., Ltd. Antipruritics
TW200306155A (en) 2002-03-19 2003-11-16 Du Pont Benzamides and advantageous compositions thereof for use as fungicides
US7442685B2 (en) 2003-06-13 2008-10-28 The University Of North Carolina At Chapel Hill DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia
RU2006138036A (en) * 2004-03-30 2008-05-10 Чирон Корпорейшн (Us) SUBSTITUTES OF SUBSTITUTED THIOPHENE AS ANTI-CANCER AGENTS
ATE449168T1 (en) 2004-06-01 2009-12-15 Univ North Carolina RECONSTITUTED HISTONE METHYLTRANSFERASE COMPLEX AND METHOD FOR IDENTIFYING MODULATORS THEREOF
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Substituted Amid derivatives & methods of use
EP1891434B1 (en) 2005-06-02 2011-01-05 The University of North Carolina at Chapel Hill Purification, characterization and reconstitution of a ubiquitin e3 ligase
FR2889526B1 (en) 2005-08-04 2012-02-17 Aventis Pharma Sa SUBSTITUTED 7-AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PROCESS FOR PRODUCTION AND USE
BRPI0618417A2 (en) 2005-10-19 2012-07-31 Gruenenthal Chemie new vanillary receptor ligands and their use to produce drugs
BRPI0617655A2 (en) 2005-10-21 2016-08-23 Merck & Co Inc compound or a pharmaceutically acceptable salt thereof, or an optical isomer thereof, use of a compound, and pharmaceutical formulation
AU2006308957B2 (en) 2005-10-28 2012-04-12 The University Of North Carolina At Chapel Hill Protein demethylases comprising a JmjC domain
EP1966141A1 (en) 2005-12-14 2008-09-10 Brystol-Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
CA2623271A1 (en) 2006-01-20 2007-08-02 The University Of North Carolina At Chapel Hill Interaction between dot1l polypeptide and calm-af10 fusion protein as a therapeutic target for leukemia
CA2650329A1 (en) 2006-05-15 2008-06-19 Irm Llc Terephthalamate compounds and compositions, and their use as hiv integrase inhibitors
CA2652634A1 (en) 2006-05-18 2007-11-29 Amphora Discovery Corporation Certain substituted quinolones, compositions, and uses thereof
US8022246B2 (en) 2006-10-10 2011-09-20 The Burnham Institute For Medical Research Neuroprotective compositions and methods
CA2676173A1 (en) 2007-02-16 2008-08-28 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
EP2137158A4 (en) 2007-02-28 2012-04-18 Methylgene Inc Small molecule inhibitors of protein arginine methyltransferases (prmts)
WO2008113006A1 (en) 2007-03-14 2008-09-18 Xenon Pharmaceuticals Inc. Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions
DE102007017884A1 (en) 2007-04-13 2008-10-16 Grünethal GmbH Novel vanilloid receptor ligands and their use in the preparation of medicines
WO2009006577A2 (en) 2007-07-03 2009-01-08 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
DE102007047737A1 (en) * 2007-10-05 2009-04-30 Merck Patent Gmbh Piperidine and piperazine derivatives
CA2703909A1 (en) 2007-10-31 2009-05-07 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
NZ586418A (en) 2007-12-19 2012-09-28 Cancer Rec Tech Ltd Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
WO2009124137A2 (en) 2008-04-01 2009-10-08 Mount Sinai School Of Medicine Of New York University Method of suppressing gene transcription through histone lysine methylation
US20100113415A1 (en) 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
AU2009279616A1 (en) 2008-08-08 2010-02-11 New York Blood Center Small molecule inhibitors of retroviral assembly and maturation
FR2934995B1 (en) 2008-08-14 2010-08-27 Sanofi Aventis POLYSUBSTITUTED AZETIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
WO2010111653A2 (en) 2009-03-27 2010-09-30 The Uab Research Foundation Modulating ires-mediated translation
US20110021362A1 (en) 2009-07-20 2011-01-27 Constellation Pharmaceuticals Agents for stimulating activity of methyl modifying enzymes and methods of use thereof
CA2784899A1 (en) 2009-12-30 2011-07-07 Avon Products, Inc. Topical lightening composition and uses thereof
WO2011140325A1 (en) * 2010-05-07 2011-11-10 Glaxosmithkline Llc Indazoles
US8637509B2 (en) * 2010-05-07 2014-01-28 Glaxosmithkline Llc Azaindazoles
MX2012012966A (en) * 2010-05-07 2013-01-22 Glaxosmithkline Llc Indoles.
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
RU2765155C2 (en) 2010-09-10 2022-01-26 Эпизайм, Инк. Human ezh2 inhibitors and methods for application thereof
WO2012068589A2 (en) 2010-11-19 2012-05-24 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
US8765792B2 (en) 2010-12-01 2014-07-01 Glaxosmithkline Llc Indoles
CN103339139A (en) 2010-12-03 2013-10-02 Epizyme股份有限公司 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
AU2012223448B2 (en) 2011-02-28 2017-03-16 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (en) 2011-04-13 2019-10-20 Epizyme Inc Aryl- or heteroaryl-substituted benzene compounds
TWI598336B (en) 2011-04-13 2017-09-11 雅酶股份有限公司 Substituted benzene compounds
CA2867282C (en) 2012-03-12 2024-04-02 Epizyme, Inc. Inhibitors of human ezh2, and methods of use thereof
JP6340361B2 (en) 2012-04-13 2018-06-06 エピザイム，インコーポレイティド Combination therapy to treat cancer
KR20220123339A (en) 2012-04-13 2022-09-06 에피자임, 인코포레이티드 Salt form of a human histone methyltransferase ezh2 inhibitor
WO2013173441A2 (en) 2012-05-16 2013-11-21 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
NZ746054A (en) 2012-10-15 2020-07-31 Epizyme Inc Methods of treating cancer
FI3057962T3 (en) 2013-10-16 2023-11-03 Epizyme Inc Hydrochloride salt form for ezh2 inhibition

Also Published As

Publication number Publication date
US20230140327A1 (en) 2023-05-04
CA2870005C (en) 2021-06-22
PT3184523T (en) 2019-09-26
EP3184523B1 (en) 2019-06-19
EP3184523A1 (en) 2017-06-28
DK3628670T3 (en) 2022-12-05
IL296199A (en) 2022-11-01
US10245269B2 (en) 2019-04-02
CY1122883T1 (en) 2022-03-24
IL235045B (en) 2019-05-30
IL282732B2 (en) 2023-04-01
WO2013155317A1 (en) 2013-10-17
SG10201912109QA (en) 2020-02-27
ES2745016T3 (en) 2020-02-27
EP3628670A1 (en) 2020-04-01
EP2836491A1 (en) 2015-02-18
IL266165A (en) 2019-06-30
LT2836491T (en) 2017-03-27
PT3628670T (en) 2022-12-02
MX362339B (en) 2019-01-11
CN104603130A (en) 2015-05-06
PL3628670T3 (en) 2023-02-20
IL282732B (en) 2022-12-01
JP6634058B2 (en) 2020-01-22
CN104603130B (en) 2018-04-27
RS59392B1 (en) 2019-11-29
US9394283B2 (en) 2016-07-19
HRP20191653T1 (en) 2020-02-21
ES2617379T3 (en) 2017-06-16
KR20200066380A (en) 2020-06-09
RU2014145544A (en) 2016-06-10
HRP20170295T1 (en) 2017-04-21
HUE031976T2 (en) 2017-08-28
SI2836491T1 (en) 2017-06-30
RS55690B1 (en) 2017-07-31
EP4190777A1 (en) 2023-06-07
MX2014012380A (en) 2015-07-23
SI3184523T1 (en) 2020-04-30
EP2836491A4 (en) 2015-09-16
RU2658911C2 (en) 2018-06-26
US20170143729A1 (en) 2017-05-25
IL266165B (en) 2021-06-30
KR102120883B1 (en) 2020-06-09
AU2013245878A1 (en) 2014-10-30
IL296199B1 (en) 2024-08-01
PL2836491T3 (en) 2017-08-31
KR102438340B1 (en) 2022-08-30
HUE045353T2 (en) 2019-12-30
AU2018200168B2 (en) 2019-08-29
US20210137936A1 (en) 2021-05-13
BR112014025508B1 (en) 2020-11-17
CA2870005A1 (en) 2013-10-17
CN108358899B (en) 2021-07-27
JP2018002742A (en) 2018-01-11
NZ700761A (en) 2016-09-30
US10821113B2 (en) 2020-11-03
DK3184523T3 (en) 2019-08-19
EP2836491B1 (en) 2016-12-07
LT3184523T (en) 2020-02-10
IL282732A (en) 2021-06-30
EP3628670B1 (en) 2022-10-12
PT2836491T (en) 2017-02-08
DK2836491T3 (en) 2017-03-06
US20180243316A1 (en) 2018-08-30
JP2015512942A (en) 2015-04-30
KR20220123339A (en) 2022-09-06
AU2018200168A1 (en) 2018-02-01
ES2931316T3 (en) 2022-12-28
AU2013245878B2 (en) 2017-10-12
KR20150002730A (en) 2015-01-07
CY1119383T1 (en) 2018-02-14
PL3184523T3 (en) 2019-12-31
SG10201608577RA (en) 2016-12-29
HUE060881T2 (en) 2023-04-28
JP6255382B2 (en) 2017-12-27
SG11201406468YA (en) 2015-01-29
US20150065503A1 (en) 2015-03-05
US20190269692A1 (en) 2019-09-05
US9872862B2 (en) 2018-01-23
JP2018199740A (en) 2018-12-20
US11491163B2 (en) 2022-11-08
CN108358899A (en) 2018-08-03
IL235045A0 (en) 2014-12-31

Similar Documents

Publication Publication Date Title
IN2014DN09068A (en)
SG10201901977XA (en) Hydrochloride salt form for ezh2 inhibition
PH12015502031A1 (en) Tetrahydropyrrolothiazine compounds
CO7400871A2 (en) Heteroaryl substituted pyridyl compounds useful as kinase modulators
PE20151752A1 (en) HETEROCYCLIC AMIDES AS KINASE INHIBITORS
PE20151794A1 (en) 1,3-OXAZIN-2-AMINE COMPOUNDS FUSED WITH PERFLUORATED CYCLOPROPYL AS BETA-SECRETASE INHIBITORS AND METHODS OF USE
RS54526B1 (en) Pyrazolospiroketone derivatives for use as acetyl-coa carboxylase inhibitors
RS54730B1 (en) Inhibitors of beta-secretase
MX2016007861A (en) Dimethylbenzoic acid compounds.
JO3318B1 (en) Bace inhibitors
UA114325C2 (en) PHENOXYETHYLPIPERIDINE COMPOUNDS
NZ709986A (en) Pharmaceutical compositions comprising nitroxyl donors
UA113638C2 (en) 4- (Benzoimidazol-2-yl) -THIAZOLE COMPOUNDS AND RELATED NES
EA201201082A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING N- (2-CHLOR-6-METHYLPHENYL) -2 - [[6- [4- (2-HYDROXYETHYL) -1-PIPERASINYL] -2-METHYL-4-PYRIMIDINYL] AMON) ch) ch)
PH12015502032A1 (en) Azetidinyloxyphenylpyrrolidine compounds
EA201591915A1 (en) COMPOUNDS OF PHENOXYETHYL DIHYDRO-1H-IZOHINOLINA
TN2013000354A1 (en) Synthesis of 2-carboxamide cycloamino urea derivatives
MX343077B (en) Novel octahydrothienoquinoline derivative, pharmaceutical composition comprising derivative, and use of these.
IN2013MU03565A (en)
PE20142433A1 (en) PROCESS FOR THE ELABORATION OF A CYCLIC DEECAPEPTIDES
UA79385U (en) Process for the preparation of (((2-r-1,3-thiazole-4-yl)methyl)sulfanyl)-azole derivatives
UA69858U (en) 2-[5-(4-dimethylaminobenzylidene)-2,4-dioxothiazolidine-3-yl]-n-[5-(4-methoxyphenyl)-1,3,4-oxadiazole -2-yl]acetamide exhibiting anticancer activity
UA86566U (en) N-hydroxyhomoazaadamantanone and dioxomolybdenum complex thereof